"159 ||| DISCUSSION ||| 4.11 ||| SDF-1α-modified MSCs enhanced the tolerance of engrafted MSCs to hypoxic injury in vitro and improved their viability in a rat model of infarcted hearts, thus helping preserve the contractile function and attenuate LV remodeling (27).",sdf-1-modified mscs enhanced tolerance engrafted mscs hypoxic injury vitro improved viability rat model infarcted hearts helping preserve contractile function attenuate lv remodeling 27,C0392747|C2248778|C2349975|C0013220|G0000000|C2248778|C0242184|C3263722|C1533691|C0184511|C0443348|C0034693|C3161035|C0333541|C0018787|G0000000|G0000000|C0026820|C0031843|C0599946|C0023128|G0000000|C0450371
135 ||| RESULTS ||| 3.25 ||| There were no serious inflammatory reactions or bleeding complications at the site of iliac puncture after BM aspiration.,inflammatory reactions bleeding complications site iliac puncture bm aspiration,C0333348|C0443286|C0019080|C0009566|C0205145|C0020889|C0033119|C0006416|C0220787
83 ||| MATERIALS AND METHODS ||| 1.49 ||| Total acquisition time was ~20 min.,total acquisition time ~20 min,C0439175|C1706701|C0040223|C0450371|C0702093
"12 |||  ||| 0.12 ||| However, there is still argumentative for the safety and efficacy of MSCs in the AMI setting.",argumentative safety efficacy mscs ami setting,G0000000|C0036043|C1280519|C2248778|G0000000|C0542559
58 ||| MATERIALS AND METHODS ||| 1.24 ||| Alkaline phosphatase staining was used to demonstrate the osteogenic differentiation.,alkaline phosphatase staining demonstrate osteogenic differentiation,C1979842|C0031678|C0487602|G0000000|C0029433|C0007589
107 ||| Ethics statement ||| 2.2 ||| The institutional review board of each participating center approved the treatment protocol before the initiation of enrollment.,institutional review board participating center approved treatment protocol initiation enrollment,C0018704|C0282443|C0972401|C0679823|C0205099|C0205540|C0039798|C0442711|C0589507|C1516879
131 ||| RESULTS ||| 3.21 ||| The absolute change in global LVEF from baseline to 6 months was significantly improved in the MSCs group than the control group.,absolute change global lvef baseline 6 months improved mscs control,C0205344|C0392747|C0205246|C0428772|C0168634|G0000000|C0439231|C0184511|C2248778|C0243148
141 ||| RESULTS ||| 3.31 ||| Symptom to initial SPECT (day) 5.1 ± 2.3 4.8 ± 2.0 0.578 Symptom to follow-up SPECT (day) 185.3 ± 7.5 182.4 ± 9.2 0.184 Symptom to initial Echo (day),symptom initial spect day 5 1 2 3 4 8 2 0 0 578 symptom follow-up spect day 185 3 7 5 182 4 9 2 0 184 symptom initial echo day,C1457887|C0205265|C0040399|C0332173|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061|C1457887|C0589120|C0040399|C0332173|C1442061|G0000000|G0000000|G0000000|C1442061|G0000000|G0000000|G0000000|G0000000|C1442061|C1457887|C0205265|C0058928|C0332173
"32 |||  ||| 0.32 ||| Therefore, we hypothesized that treatment with purified BM-derived MSCs would be effective in patients with AMI despite of delayed administration.",hypothesized treatment purified bm-derived mscs effective patients ami delayed administration,G0000000|C0039798|C1998793|C0006416|C2248778|C1280519|C0030705|G0000000|C0205421|C0001554
127 ||| RESULTS ||| 3.17 ||| Twenty-one patients of the stem cell group and 20 patients of the control group were analyzed.,twenty-one patients stem cell 20 patients control analyzed,C3715213|C0030705|C0242767|C0007634|C0450371|C0030705|C0243148|C0936012
70 ||| MATERIALS AND METHODS ||| 1.36 ||| Follow-up visit and endpoints,follow-up visit endpoints,C0589120|C0545082|C2349179
197 ||| DISCUSSION ||| 4.49 ||| Long-term follow-up is needed to define the safety and beneficial effect of MSCs.,long-term follow-up define safety beneficial mscs,C0443252|C0589120|G0000000|C0036043|G0000000|C2248778
204 ||| DISCLOSURE ||| 5.5 ||| Procedural characteristics between the MSCs group and control group,procedural characteristics mscs control,C0025664|C1521970|C2248778|C0243148
77 ||| MATERIALS AND METHODS ||| 1.43 ||| MI was defined following the consensus statement of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Redefinition of Myocardial Infarction for clinical trials on coronary intervention (19).,mi defined consensus statement joint european society cardiology esc /american college cardiology acc /american heart association aha /world heart federation whf task force redefinition myocardial infarction clinical trials coronary intervention 19,C3810814|C1704788|C0376298|C1710187|C0022417|C0239307|C0037455|C0007189|C1851476|C0596070|C0557806|C0007189|C0175754|C0596070|C0018787|C0004083|C0050451|C2700280|C0018787|G0000000|G0000000|C3540678|C0441722|G0000000|C0027061|C0021308|C0205210|C0008976|C0018787|C0886296|C0450371
119 ||| RESULTS ||| 3.9 ||| Rescue PCI was done in 1 out of 7 patients because of reperfusion failure.,rescue pci 1 7 patients reperfusion failure,G0000000|C4049621|G0000000|G0000000|C0030705|C0035124|C0231174
"118 ||| RESULTS ||| 3.8 ||| Primary PCI was carried out in most cases, except 7 patients treated with thrombolytic agents (Table 2).",primary pci carried 7 patients treated thrombolytic agents table 2,C0205225|C4049621|C0206243|G0000000|C0030705|C1522326|C0016018|C0450442|C0039224|G0000000
"130 ||| RESULTS ||| 3.20 ||| Baseline LVEF was similar between the two groups (49.0% ± 11.7% in the MSCs group, and 52.3% ± 9.3% in the control group, P = 0.247) ( Table 4).",baseline lvef 49 0% 11 7% mscs 52 3% 9 3% control = 0 247 table 4,C0168634|C0428772|C0450371|G0000000|C0450371|G0000000|C2248778|C0450371|G0000000|G0000000|G0000000|C0243148|G0000000|G0000000|C1442061|C0039224|G0000000
"200 ||| DISCLOSURE ||| 5.1 ||| FCB-Pharmicell Company Limited (Seongnam, Korea) supported this study but played no role in the study design, data collection, data analysis and interpretation, manuscript writing, and decision to proceed with publication.",fcb-pharmicell company limited seongnam korea supported study played role study design data collection data analysis interpretation manuscript writing decision proceed publication,G0000000|C0683757|C0439801|G0000000|C0022771|C1521721|C0557651|C0600138|C0035820|C0557651|C1707689|C1511726|C1516698|C1511726|C0002778|C0459471|C0600659|C0043266|C0679006|G0000000|C0034036
"23 |||  ||| 0.23 ||| Nevertheless, delayed treatment leads to subsequent loss of cardiomyocyte and heart failure, which is a major cause of long term morbidity and mortality.",delayed treatment leads subsequent loss cardiomyocyte heart failure major term morbidity mortality,C0205421|C0039798|C0023175|C0332282|C1517945|C0225828|C0018787|C0231174|C0205082|C0233324|C0026538|C0026565
4 |||  ||| 0.4 ||| Eighty patients with AMI after successful reperfusion therapy were randomly assigned and received an intracoronary administration of autologous BM-derived MSCs into the infarct related artery at 1 month.,patients ami successful reperfusion therapy randomly assigned received intracoronary administration autologous bm-derived mscs infarct artery 1 month,C0030705|G0000000|C0597535|C0035124|C0039798|G0000000|C1516050|C1514756|C0595454|C0001554|C0439859|C0006416|C2248778|C0021308|C0003842|G0000000|C0332177
"72 ||| MATERIALS AND METHODS ||| 1.38 ||| Coronary angiography, electrocardiogram-gated single-photon emission computed tomography (SPECT) and echocardiography were done at baseline and 6 months.",coronary angiography electrocardiogram-gated single-photon emission computed tomography spect echocardiography baseline 6 months,C0018787|C0002978|C0013798|C0037179|C0233929|C1441526|C0040395|C0040399|C0013516|C0168634|G0000000|C0439231
143 ||| RESULTS ||| 3.33 ||| Values are expressed as mean ± SD or number of patients (%).,values expressed sd patients %,C0042295|G0000000|C2699239|C0030705|G0000000
104 ||| MATERIALS AND METHODS ||| 1.70 ||| Statistical significance was set at P < 0.05.,statistical significance set < 0 05,C0038215|C0237881|C0036849|G0000000|G0000000|C0450371
45 ||| MATERIALS AND METHODS ||| 1.11 ||| Cultures were maintained at 37°C in a humidified atmosphere containing 5% CO2.,cultures maintained 37c humidified atmosphere 5% co2,C0010453|C1314677|G0000000|G0000000|C0004178|G0000000|G0000000
120 ||| RESULTS ||| 3.10 ||| There were no significant differences in procedural characteristics and time intervals from chest pain onset to treatment (Table 3).,differences procedural characteristics time intervals chest pain onset treatment table 3,C1705241|C0025664|C1521970|C0040223|C1272706|C0817096|C0030193|C0206132|C0039798|C0039224|G0000000
"123 ||| RESULTS ||| 3.13 ||| Echocardiographic evaluation revealed a significant increase in LVEF from baseline to 6 months in the MSCs group but not in the control group (1.9% ± 2.7% and 0.5% ± 1.8%, P < 0.001).",echocardiographic evaluation revealed increase lvef baseline 6 months mscs control 1 9% 2 7% 0 5% 1 8% < 0 001,C0013516|C0220825|C0443289|C0442805|C0428772|C0168634|G0000000|C0439231|C2248778|C0243148|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061
"153 ||| DISCUSSION ||| 4.5 ||| However, it is uncertain whether the relatively small increase in systolic function is meaningful in real-life situations (and not just a statistical difference).",uncertain increase systolic function meaningful real-life situations statistical difference,C0087130|C0442805|C0039155|C0031843|C0876919|C0237400|G0000000|C0038215|C1705241
196 ||| DISCUSSION ||| 4.48 ||| Our study group showed a relatively preserved LV systolic function and low risk profiles.,study preserved lv systolic function low risk profiles,C0557651|C0033085|C0023128|C0039155|C0031843|C0205251|C0035647|C1979963
"106 ||| Ethics statement ||| 2.1 ||| This study (SEED-MSC) was a randomized, open-label, multicenter phase-II/III clinical trial, which was approved by the Kohttp://jkms.org rean Food and Drug Administration (KFDA) and registered with clinicaltrials.gov, number NCT01392105.",study seed-msc randomized open-label multicenter phase-ii/iii clinical trial approved kohttp //jkms org rean food drug administration kfda registered clinicaltrials gov nct01392105,C0557651|C0036563|C0034656|C1709323|C0439743|C0441771|C0205210|C0008976|C0205540|G0000000|G0000000|C1522486|G0000000|C0016452|C0013227|C0001554|G0000000|C1514821|G0000000|C1419208|G0000000
"71 ||| MATERIALS AND METHODS ||| 1.37 ||| Study visits were scheduled at 1, 2, and 6 months after hospital admission for the clinical and functional evaluation.",study visits scheduled 1 2 6 months hospital admission clinical functional evaluation,C0557651|C0545082|C0086960|G0000000|G0000000|G0000000|C0439231|C0019994|C0184666|C0205210|C0205245|C0220825
121 ||| RESULTS ||| 3.11 ||| LV function as revealed by echocardiography,lv function revealed echocardiography,C0023128|C0031843|C0443289|C0013516
"38 ||| MATERIALS AND METHODS ||| 1.4 ||| We excluded patients with cardiogenic shock, life-threatening arrhythmia, advanced renal or hepatic dysfunction, history of previous coronary artery bypass graft, history of hematologic disease and malignancy, major bleeding requiring blood transfusion, stroke or transient ischemic attack in the previous 6 months, use of corticosteroids or antibiotics during the previous month, major surgical procedure in the previous 3 months, cardiopulmonary resuscitation for > 10 min within the previous 2 weeks, positive skin test for penicillin, positive result for viral markers (human immunodeficiency virus [HIV], hepatitis B virus [HBV], hepatitis C virus [HCV] and Venereal Disease Research Laboratory [VDRL] test), pregnant woman and possible candidate for pregnancy.",excluded patients cardiogenic shock life-threatening arrhythmia advanced renal hepatic dysfunction history previous coronary artery bypass graft history hematologic disease malignancy major bleeding requiring blood transfusion stroke transient ischemic attack previous 6 months corticosteroids antibiotics previous month major surgical procedure previous 3 months cardiopulmonary resuscitation 10 min previous 2 weeks positive skin test penicillin positive result viral markers human immunodeficiency virus hiv hepatitis virus hbv hepatitis virus hcv venereal disease laboratory vdrl test pregnant woman candidate pregnancy,C1554077|C0030705|C1749797|C0036974|C1517874|C0003811|C0205179|C0022646|C0205054|C0031847|C0019664|C0205156|C0018787|C0003842|C0741847|C0181074|C0019664|C0018943|C0012634|C0006826|C0205082|C0019080|G0000000|C0005767|C0005841|C0038454|C0040704|C0475224|C0277793|C0205156|G0000000|C0439231|C0001617|C0003232|C0205156|C0332177|C0205082|C0543467|C0184661|C0205156|G0000000|C0439231|C0553534|C0035273|C0450371|C0702093|C0205156|G0000000|C0439230|C0439178|C0444099|C0022885|C0030827|C0439178|C1274040|C0521026|C0005516|C0086418|C0021051|C0042776|C0019682|C0019158|C0042776|G0000000|C0019158|C0042776|C0220847|G0000000|C0012634|C0022877|C0201406|C0022885|C0549206|C0043210|G0000000|C0032961
"137 ||| RESULTS ||| 3.27 ||| There were no serious procedural complications related to intracoronary administration of MSCs, such as ventricular arrhythmias, thrombus formation or dissection.",procedural complications intracoronary administration mscs ventricular arrhythmias thrombus formation dissection,C0025664|C0009566|C0595454|C0001554|C2248778|C0018827|C0003811|C0087086|C0220781|C0012737
178 ||| DISCUSSION ||| 4.30 ||| This limitation may attenuate the efficacy of intracoronary purified MSCs.,limitation attenuate efficacy intracoronary purified mscs,C0449295|C0599946|C1280519|C0595454|C1998793|C2248778
202 ||| DISCLOSURE ||| 5.3 ||| Assessment of left ventricular (,assessment left ventricular,C1261322|C0205091|C0018827
16 |||  ||| 0.16 ||| The primary endpoint was changes in left ventricular ejection fraction (LVEF) by single-photon emission computed tomography (SPECT) at 6 month.,primary endpoint left ventricular ejection fraction lvef single-photon emission computed tomography spect 6 month,C0205225|C2349179|C0205091|C0018827|C0302131|C1264633|C0428772|C0037179|C0233929|C1441526|C0040395|C0040399|G0000000|C0332177
82 ||| MATERIALS AND METHODS ||| 1.48 ||| Acquisitions were attenuation-corrected and gated for 16 frames/cardiac cycle.,acquisitions attenuation-corrected gated 16 frames/cardiac cycle,C1706701|C0599946|G0000000|C0450371|C0180979|C1511572
"113 ||| RESULTS ||| 3.3 ||| After enrollment, 11 patients were excluded for the reasons listed in Fig.",enrollment 11 patients excluded reasons listed fig,C1516879|C0450371|C0030705|C1554077|C0392360|C0745732|C0349966
"2 |||  ||| 0.2 ||| However, there is still argumentative for the safety and efficacy of MSCs in the AMI setting.",argumentative safety efficacy mscs ami setting,G0000000|C0036043|C1280519|C2248778|G0000000|C0542559
"150 ||| DISCUSSION ||| 4.2 ||| The stem cell therapy for AMI increased LVEF by 2.99% (95% confidence interval [CI], 1.26%-4.72%, P = 0.0007) in meta-analysis (4).",stem cell therapy ami increased lvef 2 99% 95% confidence interval ci 1 26%-4 72% = 0 0007 meta-analysis 4,C0242767|C0007634|C0039798|G0000000|C0205217|C0428772|G0000000|C0450371|C0450371|C0237529|C1272706|C0008107|G0000000|C0450371|C0450371|G0000000|G0000000|G0000000|C0282458|G0000000
"78 ||| MATERIALS AND METHODS ||| 1.44 ||| Hence, periprocedural MI was defined as the levels of cardiac biomarkers (troponin or creatine kinase-MB [CK-MB]) > 3 times the 99th percentile of upper limit of normal (ULN) in patients with normal baseline levels, and as a subsequent elevation > 3 times in CK-MB or troponin in patients with raised baseline levels.",periprocedural mi defined levels cardiac biomarkers troponin creatine kinase-mb ck-mb 3 times 99th percentile upper limit normal uln patients normal baseline levels subsequent elevation 3 times ck-mb troponin patients raised baseline levels,G0000000|C3810814|C1704788|C0441889|C0018787|C0005516|C0041199|C0010286|C0031727|C0010290|G0000000|C0040223|G0000000|C1264641|C1282910|C0439801|C0205307|C1519815|C0030705|C0205307|C0168634|C0441889|C0332282|C0439775|G0000000|C0040223|C0010290|C0041199|C0030705|C0442818|C0168634|C0441889
117 ||| RESULTS ||| 3.7 ||| The Killip classification and angiographic characteristics including IRA were also similar between two groups.,killip classification angiographic characteristics including ira,G0000000|C0008902|C0002978|C1521970|C0332257|C1512960
"173 ||| DISCUSSION ||| 4.25 ||| Mortality reduction was greatest in the first 2-3 hr after the onset of AMI, as a consequence of myocardial salvage (31).",mortality reduction 2-3 hr onset ami consequence myocardial salvage 31,C0026565|C0301630|G0000000|G0000000|C0206132|G0000000|C0686907|C0027061|C0085405|C0450371
110 ||| Ethics statement ||| 2.5 ||| There were no significant differences with regard to WMSI and change in WMSI.,differences regard wmsi change wmsi,C1705241|G0000000|G0000000|C0392747|G0000000
166 ||| DISCUSSION ||| 4.18 ||| Further clinical randomized trials need to confirm the optimal time to treatment.,clinical randomized trials confirm optimal time treatment,C0205210|C0034656|C0008976|C0521093|C2698651|C0040223|C0039798
"28 |||  ||| 0.28 ||| Second, most studies were performed around 1 week after AMI with autologous bone marrow-derived progenitor cells (BMCs) (7)(8)(9)(10)(11)(12).",studies performed 1 week ami autologous bone marrow-derived progenitor cells bmcs 7 8 9 10 11 12,C0947630|C0884358|G0000000|C0332174|G0000000|C0439859|C0262950|C0086590|C0870134|C0007634|C0065839|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371
115 ||| RESULTS ||| 3.5 ||| Two patients were excluded because of long-term medication of prohibited drug (corticosteroid).,patients excluded long-term medication prohibited drug corticosteroid,C0030705|C1554077|C0443252|C0013227|C0138547|C0013227|C0001617
"27 |||  ||| 0.27 ||| However, the practical use of MSCs is limited because of time-consuming processes, expensive cost, need for strict control of infection and so on.",practical mscs limited time-consuming processes expensive cost strict control infection,G0000000|C2248778|C0439801|C3827829|C1184743|C0680864|C0010186|G0000000|C0243148|C0009450
182 ||| DISCUSSION ||| 4.34 ||| We therefore measured LVEF with SPECT because we concluded that software-based automated analysis using SPECT could minimize inter-observer variability.,measured lvef spect concluded software-based automated analysis spect minimize inter-observer variability,C0444706|C0428772|C0040399|C0917903|C0037585|C0205554|C0002778|C0040399|G0000000|C0205103|C2827666
185 ||| DISCUSSION ||| 4.37 ||| Total patients of exclusion were 22/80 (27.5%).,total patients exclusion 22/80 27 5%,C0439175|C0030705|C0680251|C0450371|C0450371|G0000000
17 |||  ||| 0.17 ||| We also evaluated treatment-related adverse events.,evaluated treatment-related adverse events,C0220825|C0039798|G0000000|C0441471
54 ||| MATERIALS AND METHODS ||| 1.20 ||| Patients who were successfully reperfused with thrombolytic agents underwent elective PCI.,patients reperfused thrombolytic agents underwent elective pci,C0030705|G0000000|C0016018|C0450442|G0000000|C0206058|C4049621
114 ||| RESULTS ||| 3.4 ||| The main cause of exclusion during follow-up was poor image quality.,main exclusion follow-up poor image quality,C0205225|C0680251|C0589120|C0032854|C1704254|C0332306
25 |||  ||| 0.25 ||| The type and time of administration of stem cells are important issues.,type time administration stem cells issues,C0332307|C0040223|C0001554|C0242767|C0007634|C0033213
139 ||| RESULTS ||| 3.29 ||| The peak levels of CK-MB and troponin I were 2.38    (90) 28 (100) 28 (100) 5 ( 1.4 ± 0.6 3.08 ± 0.50 31.9 ± 12.9,peak levels ck-mb troponin 2 38 90 28 100 28 100 5 1 4 0 6 3 08 0 50 31 9 12 9,C0444505|C0441889|C0010290|C0041199|G0000000|C0450371|C0450371|C0450371|C1442061|C0450371|C1442061|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|G0000000|C0450371|C0450371|G0000000|C0450371|G0000000
"184 ||| DISCUSSION ||| 4.36 ||| Third, many patients were excluded from this study.",patients excluded study,C0030705|C1554077|C0557651
"177 ||| DISCUSSION ||| 4.29 ||| First, our study enrolled relatively small number of patients.",study enrolled patients,C0557651|G0000000|C0030705
74 ||| MATERIALS AND METHODS ||| 1.40 ||| The primary endpoint of the study was absolute changes in global LVEF from baseline to 6 months after the MSCs administration measured by SPECT.,primary endpoint study absolute global lvef baseline 6 months mscs administration measured spect,C0205225|C2349179|C0557651|C0205344|C0205246|C0428772|C0168634|G0000000|C0439231|C2248778|C0001554|C0444706|C0040399
191 ||| DISCUSSION ||| 4.43 ||| The selection of inappropriate images was left at the discretion of radiologists.,selection inappropriate images left discretion radiologists,C0036576|C1548788|C1704254|C0205091|G0000000|C0260194
"80 ||| MATERIALS AND METHODS ||| 1.46 ||| System, Tel Aviv, Israel) equipped with a low-energy, high-resolution collimator.",system tel aviv israel equipped low-energy high-resolution collimator,C0449913|C0254343|G0000000|C0022271|G0000000|C0205251|C1719039|C0454169
"157 ||| DISCUSSION ||| 4.9 ||| Numerous in vitro and in vivo studies have shown the pleiotropic effects of MSCs such as antifibrotic, immunomodulatory, antiapototic and proangiogenic features as well as the impact of inflammation/cytokine expression on the different aspects of homing, including chemokine-chemokine receptor interactions, adhesion on endothelial cells, transendothelial migration, and invasion through the extracellular matrix (26).",numerous vitro vivo studies pleiotropic effects mscs antifibrotic immunomodulatory antiapototic proangiogenic features impact inflammation/cytokine expression aspects homing including chemokine-chemokine receptor interactions adhesion endothelial cells transendothelial migration invasion extracellular matrix 26,C0439064|C1533691|C1515655|C0947630|G0000000|C1280500|C2248778|G0000000|G0000000|G0000000|G0000000|C1521970|C1825598|C0021368|C0185117|C1547011|G0000000|C0332257|C0282554|C0597357|C1704675|C0001511|C0014257|C0007634|G0000000|C0600210|C1269955|C0521119|C1704640|C0450371
14 |||  ||| 0.14 ||| Eighty patients with AMI after successful reperfusion therapy were randomly assigned and received an intracoronary administration of autologous BM-derived MSCs into the infarct related artery at 1 month.,patients ami successful reperfusion therapy randomly assigned received intracoronary administration autologous bm-derived mscs infarct artery 1 month,C0030705|G0000000|C0597535|C0035124|C0039798|G0000000|C1516050|C1514756|C0595454|C0001554|C0439859|C0006416|C2248778|C0021308|C0003842|G0000000|C0332177
"57 ||| MATERIALS AND METHODS ||| 1.23 ||| Also, the in vitro osteogenic and cardiomyogenic differentiation potential of MSCs in passage 0 or 1 was tested before release as a potency test.",vitro osteogenic cardiomyogenic differentiation potential mscs passage 0 1 tested release potency test,C1533691|C0029433|G0000000|C0007589|C3245505|C2248778|C0439799|G0000000|G0000000|C0392366|C0030685|C3245505|C0022885
"90 ||| MATERIALS AND METHODS ||| 1.56 ||| The left ventricle was divided into three levels (basal, mid, apical) and 16 segments.",left ventricle divided levels basal mid apical 16 segments,C0205091|C0018827|C0332849|C0441889|C0205112|C0444598|C0205111|C0450371|C0441635
"155 ||| DISCUSSION ||| 4.7 ||| It seems to be a safe method to deliver stem cells via intracoronary route, since its introduction by Strauer et al.",safe method deliver stem cells intracoronary route introduction strauer al,G0000000|C0025663|C0308779|C0242767|C0007634|C0595454|C0013153|C1293116|G0000000|C0202311
10 |||  ||| 0.10 ||| No significant adverse cardiovascular events occurred during follow-up.,adverse cardiovascular events occurred follow-up,G0000000|C0007226|C0441471|C1709305|C0589120
"33 |||  ||| 0.33 ||| We designed a randomized, multicenter, pilot study to determine whether intracoronary infusion of autologous BM-derived MSCs at 1 month is safe and effective in patients with AMI.",designed randomized multicenter pilot study determine intracoronary infusion autologous bm-derived mscs 1 month safe effective patients ami,C1707689|C0034656|C0439743|C0473169|C0557651|G0000000|C0595454|C0574032|C0439859|C0006416|C2248778|G0000000|C0332177|G0000000|C1280519|C0030705|G0000000
87 ||| MATERIALS AND METHODS ||| 1.53 ||| Regional and global LV function were measured by two-dimensional echocardiography according to the recommendations of the American Society of Echocardiography (21).,regional global lv function measured two-dimensional echocardiography recommendations american society echocardiography 21,C0205147|C0205246|C0023128|C0031843|C0444706|C1705052|C0013516|C0034866|C0596070|C0037455|C0013516|C0450371
"66 ||| MATERIALS AND METHODS ||| 1.32 ||| Between occlusions, the coronary artery was reperfused for 3 min.",occlusions coronary artery reperfused 3 min,C0028778|C0018787|C0003842|G0000000|G0000000|C0702093
147 ||| RESULTS ||| 3.37 ||| No significant arrhythmic events were recorded on 24 hr ambulatory ECG (Holter) monitoring.,arrhythmic events recorded 24 hr ambulatory ecg holter monitoring,G0000000|C0441471|C0034869|C0450371|G0000000|C0439841|C1623258|G0000000|C0150369
61 ||| MATERIALS AND METHODS ||| 1.27 ||| Cell injection,cell injection,C0007634|C0021485
"65 ||| MATERIALS AND METHODS ||| 1.31 ||| The entire cell injection was done during three transient occlusions, each lasting 2 to 3 min.",entire cell injection transient occlusions lasting 2 3 min,C0439751|C0007634|C0021485|C0040704|C0028778|C1517741|G0000000|G0000000|C0702093
68 ||| MATERIALS AND METHODS ||| 1.34 ||| Measurements of cardiac enzymes and electrocardiography were repeated to assess periprocedural myocardial infarction (MI).,measurements cardiac enzymes electrocardiography repeated assess periprocedural myocardial infarction mi,C0242485|C0018787|C0014442|C0013798|C0205341|C1516048|G0000000|C0027061|C0021308|C3810814
1 |||  ||| 0.1 ||| Recent studies suggest that the intracoronary administration of bone marrow (BM)-derived mesenchymal stem cells (MSCs) may improve left ventricular function in patients with acute myocardial infarction (AMI).,studies intracoronary administration bone marrow bm -derived mesenchymal stem cells mscs improve left ventricular function patients acute myocardial infarction ami,C0947630|C0595454|C0001554|C0262950|C0086590|C0006416|C1441547|C1513143|C0242767|C0007634|C2248778|G0000000|C0205091|C0018827|C0031843|C0030705|C0205178|C0027061|C0021308|G0000000
51 ||| MATERIALS AND METHODS ||| 1.17 ||| The use of aspiration thrombectomy or a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention (PCI) was left to the investigator's discretion.,aspiration thrombectomy glycoprotein iib/iiia inhibitor percutaneous coronary intervention pci left investigators discretion,C0220787|C0162578|C0017968|G0000000|C1999216|C0522523|C0018787|C0886296|C4049621|C0205091|C0035173|G0000000
140 ||| RESULTS ||| 3.30 ||| 1.6 ± 0.7 3.17 ± 0.39 41.8 ± 19.,1 6 0 7 3 17 0 39 41 8 19,G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|G0000000|C0450371|C0450371|G0000000|C0450371
"99 ||| MATERIALS AND METHODS ||| 1.65 ||| Based on the assumption of 6% differences of LVEF and 1:1 allocation ratio with 27% drop-out rate, total 80 patients (40 patients in each group) are necessary.",based assumption 6% differences lvef 1 1 allocation ratio 27% drop-out rate total 80 patients 40 patients,C1527178|G0000000|G0000000|C1705241|C0428772|G0000000|G0000000|C1706778|C0456603|C0450371|C1321095|C0871208|C0439175|C0450371|C0030705|C0450371|C0030705
"180 ||| DISCUSSION ||| 4.32 ||| Second, there may be a technical problem for the assessment of LVEF.",technical assessment lvef,C0449851|C1261322|C0428772
88 ||| MATERIALS AND METHODS ||| 1.54 ||| LVEF was measured from the end-diastolic and end-systolic volumes calculated by the Simpson method from two orthogonal apical views.,lvef measured end-diastolic end-systolic volumes calculated simpson method orthogonal apical views,C0428772|C0444706|C0442709|C0489485|C0449468|C0444686|G0000000|C0025663|G0000000|C0205111|C0449911
101 ||| MATERIALS AND METHODS ||| 1.67 ||| Categorical data are presented as frequencies and percentages.,categorical data frequencies percentages,C0683312|C1511726|C0439603|C0439165
125 ||| RESULTS ||| 3.15 ||| Subgroup analyses according to time interval,subgroup analyses time interval,C1079230|C0002778|C0040223|C1272706
55 ||| MATERIALS AND METHODS ||| 1.21 ||| Patients were randomly allocated in a 1:1 cells/kg.,patients randomly allocated 1 1 cells/kg,C0030705|G0000000|G0000000|G0000000|G0000000|C3899697
"145 ||| RESULTS ||| 3.35 ||| However, they had no symptoms and spontaneously recovered without additional treatment during 6-month follow-up.",symptoms spontaneously recovered additional treatment 6-month follow-up,C0683368|G0000000|C0521108|C1524062|C0039798|C0332177|C0589120
108 ||| Ethics statement ||| 2.3 ||| All patients provided written informed consent for inclusion in the trial.,patients provided written informed consent inclusion trial,C0030705|C1999230|C0043266|C1522154|C1511481|C0007637|C0008976
95 ||| MATERIALS AND METHODS ||| 1.61 ||| Off-line assessment of all echocardiographic images was performed by one blinded independent investigator.,off-line assessment echocardiographic images performed blinded independent investigator,C1518543|C1261322|C0013516|C1704254|C0884358|C0150108|C0085862|C0035173
79 ||| MATERIALS AND METHODS ||| 1.45 ||| Target-vessel revascularization (TVR) included bypass surgery or repeat PCI of the target vessel(s).,target-vessel revascularization tvr included bypass surgery repeat pci target vessel,C0449618|C0581603|G0000000|C0332257|C0741847|C0038894|C0205341|C4049621|C1521840|C0005847
"47 ||| MATERIALS AND METHODS ||| 1.13 ||| When the cultures were near confluence (70%-80%), adherent cells were detached by using trypsin containing ethylene diamine tetra-acetic acid (EDTA; Gibco) and replated at 4-5 × 10 3 cells/cm 2 in 175 cm 2 flasks.",cultures confluence 70%-80% adherent cells detached trypsin ethylene diamine tetra-acetic acid edta gibco replated 4-5 10 3 cells/cm 2 175 cm 2 flasks,C0010453|C0205200|C0450371|C0334154|C0007634|C0687118|C0041236|C0015075|C0011957|C0039644|C0001128|C0013618|G0000000|G0000000|G0000000|C0450371|G0000000|C0007634|G0000000|C1442061|G0000000|G0000000|C0872171
"64 ||| MATERIALS AND METHODS ||| 1.30 ||| To allow the maximum contact time of MSCs with the microcirculation of the IRA, the balloon was inflated inside the stent at a low pressure to transiently interrupt antegrade blood flow during infusions.",maximum contact time mscs microcirculation ira balloon inflated inside stent low pressure transiently interrupt antegrade blood flow infusions,C0806909|C0332158|C0040223|C2248778|C0025962|C1512960|C0336867|C0021398|G0000000|C0038257|C0205251|C0033095|G0000000|C0443239|C0589502|C0005767|C0806140|C0574032
94 ||| MATERIALS AND METHODS ||| 1.60 ||| The WMSI was derived by dividing the sum of wall motion score by the number of visualized segments; a normal WMSI was 1.,wmsi derived dividing sum wall motion score visualized segments normal wmsi 1,G0000000|C1441547|C0332849|C1515051|C0677535|C0026597|C0449820|C0234621|C0441635|C0205307|G0000000|G0000000
"149 ||| DISCUSSION ||| 4.1 ||| In our study, the main finding is that the intracoronary adminhttp://jkms.org   istration of autologous purified BM-derived MSCs at 1 month after STEMI is tolerable without serious complications and provides modest improvement in LVEF at 6-month follow-up by SPECT.",study main finding intracoronary adminhttp //jkms org istration autologous purified bm-derived mscs 1 month stemi tolerable complications modest improvement lvef 6-month follow-up spect,C0557651|C0205225|C0037088|C0595454|G0000000|G0000000|C1522486|G0000000|C0439859|C1998793|C0006416|C2248778|G0000000|C0332177|C3538872|C4053931|C0009566|C4054480|C2986411|C0428772|C0332177|C0589120|C0040399
176 ||| DISCUSSION ||| 4.28 ||| Our study has several limitations.,study limitations,C0557651|C0449295
102 ||| MATERIALS AND METHODS ||| 1.68 ||| Comparisons of continuous variables at baseline with those at follow-up were done with the paired t-test.,comparisons continuous variables baseline follow-up paired t-test,C1707455|C0549178|C0439828|C0168634|C0589120|C1709450|C0871472
96 ||| MATERIALS AND METHODS ||| 1.62 ||| Study hypothesis is to demonstrate the superiority of MSCs treatment compared with control group.,study hypothesis demonstrate superiority mscs treatment compared control,C0557651|C1512571|G0000000|C0680218|C2248778|C0039798|C1707455|C0243148
179 ||| DISCUSSION ||| 4.31 ||| Further largescale randomized trials are needed.,largescale randomized trials,G0000000|C0034656|C0008976
"198 ||| DISCUSSION ||| 4.50 ||| In conclusion, this pilot study was designed to identify the safety and practical efficacy of intracoronary purified autologous BM-derived MSCs in patients with STEMI.",conclusion pilot study designed identify safety practical efficacy intracoronary purified autologous bm-derived mscs patients stemi,C1707478|C0473169|C0557651|C1707689|G0000000|C0036043|G0000000|C1280519|C0595454|C1998793|C0439859|C0006416|C2248778|C0030705|C3538872
62 ||| MATERIALS AND METHODS ||| 1.28 ||| Injection of MSCs has been described elsewhere (11).,injection mscs 11,C0021485|C2248778|C0450371
116 ||| RESULTS ||| 3.6 ||| There were no differences with respect to cardiovascular risk factors and medical treatments.,differences respect cardiovascular risk factors medical treatments,C1705241|C0679133|C0007226|C0035647|C1521761|C0199168|C0087111
"122 ||| RESULTS ||| 3.12 ||| Baseline LVEF was similar in the MSCs group and the control group (48.1% ± 8.0% and 51.0% ± 9.2%, respectively, P = 0.215).",baseline lvef mscs control 48 1% 8 0% 51 0% 9 2% = 0 215,C0168634|C0428772|C2248778|C0243148|C0450371|G0000000|G0000000|G0000000|C0450371|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061
92 ||| MATERIALS AND METHODS ||| 1.58 ||| Numerical scoring was adopted on the basis of the contractility of the individual segments.,numerical scoring basis contractility individual segments,C0237753|C0449820|C1527178|C0026820|C0027361|C0441635
30 |||  ||| 0.30 ||| Assmus et al.,assmus al,G0000000|C0202311
"75 ||| MATERIALS AND METHODS ||| 1.41 ||| Secondary endpoints were changes in left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), regional wall motion score index (WMSI) and major adverse cardiac events (MACE).",secondary endpoints left ventricular end-diastolic volume lvedv left ventricular end-systolic volume lvesv regional wall motion score wmsi major adverse cardiac events mace,C0027627|C2349179|C0205091|C0018827|C0442709|C0449468|G0000000|C0205091|C0018827|C0489485|C0449468|G0000000|C0205147|C0677535|C0026597|C0449820|G0000000|C0205082|G0000000|C0018787|C0441471|C0349381
37 ||| MATERIALS AND METHODS ||| 1.3 ||| Patients were eligible if 1) they were aged 18-70 yr; 2) they had ischemic chest pain for > 30 min; 3) they were admitted to hospital < 24 hr after the onset of chest pain; 4) electrocardiography (ECG) showed ST segment elevation > 1 mm in two consecutive leads in the limb leads or > 2 mm in the precordial leads; and 5) they could be enrolled in the study < 72 hr after successful revascularization (defined as residual stenosis < 30% of the infarct-related artery [IRA]).,patients eligible 1 aged 18-70 yr 2 ischemic chest pain 30 min 3 admitted hospital < 24 hr onset chest pain 4 electrocardiography ecg st segment elevation 1 mm consecutive leads limb leads 2 mm precordial leads 5 enrolled study < 72 hr successful revascularization defined residual stenosis < 30% infarct-related artery ira,C0030705|C1548635|G0000000|C0001779|C0450371|C0439234|G0000000|C0475224|C0817096|C0030193|C0450371|C0702093|G0000000|C0184666|C0019994|G0000000|C0450371|G0000000|C0206132|C0817096|C0030193|G0000000|C0013798|C1623258|C0036056|C0441635|C0439775|G0000000|G0000000|C1707491|C0023175|C0015385|C0023175|G0000000|G0000000|C0230134|C0023175|G0000000|G0000000|C0557651|G0000000|C0450371|G0000000|C0597535|C0581603|C1704788|C1609982|C0678234|G0000000|C0450371|C0021308|C0003842|C1512960
"24 |||  ||| 0.24 ||| In this respect, stem cell therapy has emerged as a novel alternative option for repairing the damaged myocardium (4).",respect stem cell therapy emerged alternative option repairing damaged myocardium 4,C0679133|C0242767|C0007634|C0039798|G0000000|C1523987|C1518601|C0043240|C0010957|C0027061|G0000000
"41 ||| MATERIALS AND METHODS ||| 1.7 ||| All manufacturing and product testing procedures for the generation of clinical-grade autologous MSCs were carried out under good manufacturing practice (FCB-Pharmicell Company Limited, Seongnam, Korea).",manufacturing product testing procedures generation clinical-grade autologous mscs carried manufacturing practice fcb-pharmicell company limited seongnam korea,C0870840|C1514468|C0039593|C0025664|C0079411|C0205210|C0439859|C2248778|C0206243|C0870840|C0237607|G0000000|C0683757|C0439801|G0000000|C0022771
"31 |||  ||| 0.31 ||| However, purified MSCs can be expanded from BM and have no concern about contamination.",purified mscs expanded bm concern contamination,C1998793|C2248778|C0205229|C0006416|C2699424|C0259846
19 |||  ||| 0.19 ||| There was no treatment-related toxicity during intracoronary administration of MSCs.,treatment-related toxicity intracoronary administration mscs,C0039798|C0040539|C0595454|C0001554|C2248778
22 |||  ||| 0.22 ||| Remarkable advances of early reperfusion therapy in acute myocardial infarction (AMI) have contributed to a reduction of early mortality as well as complications of post-AMI (1)(2)(3).,remarkable advances reperfusion therapy acute myocardial infarction ami contributed reduction mortality complications post-ami 1 2 3,G0000000|C0725066|C0035124|C0039798|C0205178|C0027061|C0021308|G0000000|C1880177|C0301630|C0026565|C0009566|C0687676|G0000000|G0000000|G0000000
161 ||| DISCUSSION ||| 4.13 ||| One of the main concerns is the time limitation for using autologous MSCs in acute setting.,main concerns time limitation autologous mscs acute setting,C0205225|C2699424|C0040223|C0449295|C0439859|C2248778|C0205178|C0542559
103 ||| MATERIALS AND METHODS ||| 1.69 ||| Comparison of non-parametric data between groups was undertaken using the Wilcoxon rank sum test and the Mann-Whitney test.,comparison non-parametric data undertaken wilcoxon rank sum test mann-whitney test,C1707455|C1518422|C1511726|G0000000|G0000000|C0699794|C1515051|C0022885|G0000000|C0022885
"42 ||| MATERIALS AND METHODS ||| 1.8 ||| Mononuclear cells were separated from the BM by density gradient centrifugation (HIS-TOPAQUE-1077; Sigma-Aldrich, St. Louis, MO, USA) and washed with phosphate-buffered saline (PBS).",mononuclear cells separated bm density gradient centrifugation his-topaque-1077 sigma-aldrich st louis mo usa washed phosphate-buffered saline pbs,C1513475|C0007634|C0086972|C0006416|C0178587|C0439182|C0007703|G0000000|C1719918|C0036056|G0000000|C0026544|C0041703|C1548982|C0991865|C0036082|C1720830
"193 ||| DISCUSSION ||| 4.45 ||| Fourth, we did not use diverse assessment tools such as the 6-min walking distance, exercise tolerance, pulmonary function test and quality of life.",fourth diverse assessment tools 6-min walking distance exercise tolerance pulmonary function test quality life,C0205438|C1880371|C1261322|C0336791|C0702093|C0080331|C0012751|C0015259|C0013220|C0024109|C0031843|C0022885|C0332306|C0376558
"189 ||| DISCUSSION ||| 4.41 ||| More patients in control group (5/36, 13.9%) were excluded than those in treatment group (1/33, 3.0%).",patients control 5/36 13 9% excluded treatment 1/33 3 0%,C0030705|C0243148|C0450371|C0450371|G0000000|C1554077|C0039798|C0450371|G0000000|G0000000
"195 ||| DISCUSSION ||| 4.47 ||| Sixth, there was no death in either group.",sixth death,C0205440|C0011065
98 ||| MATERIALS AND METHODS ||| 1.64 ||| The changes of LVEF and standard deviation are 6.7% ± 6.5% in BMCs group and 0.7% ± 8.1% in control group.,lvef standard deviation 6 7% 6 5% bmcs 0 7% 8 1% control,C0428772|C1442989|C0012727|G0000000|G0000000|G0000000|G0000000|C0065839|G0000000|G0000000|G0000000|G0000000|C0243148
"49 ||| MATERIALS AND METHODS ||| 1.15 ||| On the day of administration, MSCs were harvested using trypsin and EDTA, washed twice with PBS and once with saline solution, and resuspended to a final concentration of 1 × 10 6 Primary care and randomization All patients were required to have successful revascularization of an IRA on coronary angiography at the time of randomization.",day administration mscs harvested trypsin edta washed pbs saline solution resuspended final concentration 1 10 6 primary care randomization patients required successful revascularization ira coronary angiography time randomization,C0332173|C0001554|C2248778|C1512335|C0041236|C0013618|C1548982|C1720830|C0036082|C0037633|G0000000|C0205088|C0004268|G0000000|C0450371|G0000000|C0205225|C1947933|C0034656|C0030705|C1514873|C0597535|C0581603|C1512960|C0018787|C0002978|C0040223|C0034656
152 ||| DISCUSSION ||| 4.4 ||| Our results met the primary endpoint of ≥ 4.3% improvement in LVEF compared with the control group.,met primary endpoint 4 3% improvement lvef compared control,C0268621|C0205225|C2349179|G0000000|G0000000|C2986411|C0428772|C1707455|C0243148
"165 ||| DISCUSSION ||| 4.17 ||| Several experimental studies and clinical subgroup analyses provided important clues that stem cell therapy might be effective within the first month after AMI, but not in very acute phase (24 hr after AMI) (29).",experimental studies clinical subgroup analyses provided clues stem cell therapy effective month ami acute phase 24 hr ami 29,C1517586|C0947630|C0205210|C1079230|C0002778|C1999230|G0000000|C0242767|C0007634|C0039798|C1280519|C0332177|G0000000|C0205178|C0205390|C0450371|G0000000|G0000000|C0450371
"169 ||| DISCUSSION ||| 4.21 ||| The combined treatment of atorvastatin with MSCs reduced myocardial apoptosis, oxidative stress and expression of the inflammatory cytokines (30).",combined treatment atorvastatin mscs reduced myocardial apoptosis oxidative stress expression inflammatory cytokines 30,C0205195|C0039798|C0286651|C2248778|C0392756|C0027061|C0162638|C0311404|C0038435|C0185117|C0333348|C0079189|C0450371
201 ||| DISCLOSURE ||| 5.2 ||| The authors indicate no potential conflicts of interest.,authors potential conflicts,C3812881|C3245505|C0009671
34 |||  ||| 0.34 ||| Control group received optimal medical therapy alone.,control received optimal medical therapy,C0243148|C1514756|C2698651|C0199168|C0039798
132 ||| RESULTS ||| 3.22 ||| Baseline and 6 months LVEDV and LVESV showed no,baseline 6 months lvedv lvesv,C0168634|G0000000|C0439231|G0000000|G0000000
"63 ||| MATERIALS AND METHODS ||| 1.29 ||| The final preparation of MSCs (7.2 ± 0.90 × 10 7 cells) contained into sterilized syringe was gently transferred and mixed to infusion syringe to minimize cell aggregation and then infused into the IRA via the central lumen of an over-the-wire balloon catheter (Maverick ® , Boston Scientific, Natick, MA, USA).",final preparation mscs 7 2 0 90 10 7 cells contained sterilized syringe gently transferred mixed infusion syringe minimize cell aggregation infused ira central lumen over-the-wire balloon catheter maverick boston scientific natick ma usa,C0205088|C1521827|C2248778|G0000000|G0000000|G0000000|C0450371|C0450371|G0000000|C0007634|C0332256|C0038280|C0039142|C1638411|C0348011|C0205430|C0574032|C0039142|G0000000|C0007634|C0332621|G0000000|C1512960|C0205099|C0524461|C0205136|C0336867|C0085590|G0000000|C0006037|C0036397|G0000000|C0024443|C0041703
"154 ||| DISCUSSION ||| 4.6 ||| In terms of safety, intracoronary administration of MSCs showed no serious adverse events, although periprocedural MI was developed in 2 patients.",terms safety intracoronary administration mscs adverse events periprocedural mi developed 2 patients,C0233324|C0036043|C0595454|C0001554|C2248778|G0000000|C0441471|G0000000|C3810814|G0000000|G0000000|C0030705
"175 ||| DISCUSSION ||| 4.27 ||| Our subgroup analysis supports that BM-derived MSCs may help damaged myocardium to recover, if treated within 6 hr after AMI.",subgroup analysis supports bm-derived mscs damaged myocardium recover treated 6 hr ami,C1079230|C0002778|C0183683|C0006416|C2248778|C0010957|C0027061|C0521108|C1522326|G0000000|G0000000|G0000000
60 ||| MATERIALS AND METHODS ||| 1.26 ||| Qualitative analysis showed well differentiation potential of all MSCs.,qualitative analysis differentiation potential mscs,C0205556|C0002778|C0007589|C3245505|C2248778
100 ||| MATERIALS AND METHODS ||| 1.66 ||| Continuous variables are presented as mean ± standard deviation.,continuous variables standard deviation,C0549178|C0439828|C1442989|C0012727
"156 ||| DISCUSSION ||| 4.8 ||| Moreover, ischemic pre-conditioning induced by transient balloon occlusion seems to be important to recruit MSCs into the infarcted myocardium (24,25).",ischemic pre-conditioning induced transient balloon occlusion recruit mscs infarcted myocardium 24 25,C0475224|C1709632|C0205263|C0040704|C0336867|C0011382|G0000000|C2248778|C0333541|C0027061|C0450371|C0450371
172 ||| DISCUSSION ||| 4.24 ||| The total ischemic time from symptom to treatment is the most important factor related to adverse outcomes.,total ischemic time symptom treatment factor adverse outcomes,C0439175|C0475224|C0040223|C1457887|C0039798|C1521761|G0000000|C1274040
162 ||| DISCUSSION ||| 4.14 ||| It is impossible to use autologous MSCs immediately because it takes time to harvest and culture cells for over 3 weeks.,impossible autologous mscs takes time harvest culture cells 3 weeks,G0000000|C0439859|C2248778|C1515187|C0040223|C1512335|C0010453|C0007634|G0000000|C0439230
"11 |||  ||| 0.11 ||| In conclusion, the intracoronary infusion of human BM-derived MSCs at 1 month is tolerable and safe with modest improvement in LVEF at 6-month follow-up by SPECT.",conclusion intracoronary infusion human bm-derived mscs 1 month tolerable safe modest improvement lvef 6-month follow-up spect,C1707478|C0595454|C0574032|C0086418|C0006416|C2248778|G0000000|C0332177|C4053931|G0000000|C4054480|C2986411|C0428772|C0332177|C0589120|C0040399
"50 ||| MATERIALS AND METHODS ||| 1.16 ||| All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI) (16)(17)(18), including aspirin, clopidogrel, beta blocker, angiotensin-converting enzyme (ACE) inhibitor (or angiotensin-receptor blocker) and statin unless these drugs were contraindicated.",patients received aspirin 300 loading dose 100 daily clopidogrel 600 loading dose 75 daily optimal medical therapy american college cardiology acc /american heart association aha guidelines treatment st-segment elevation myocardial infarction stemi 16 17 18 including aspirin clopidogrel beta blocker angiotensin-converting enzyme ace inhibitor angiotensin-receptor blocker statin drugs contraindicated,C0030705|C1514756|C0004057|C1442061|C1708715|C0178602|C1442061|C0332173|C0070166|C1442061|C1708715|C0178602|C0450371|C0332173|C2698651|C0199168|C0039798|C0596070|C0557806|C0007189|C0175754|C0596070|C0018787|C0004083|C0050451|C0162791|C0039798|C0429029|C0439775|C0027061|C0021308|C3538872|C0450371|C0450371|C0450371|C0332257|C0004057|C0070166|C0330390|G0000000|C0003018|C0014442|C1452534|C1999216|C0034787|G0000000|C0360714|C0013227|C1444657
203 ||| DISCLOSURE ||| 5.4 ||| Baseline characteristics between the MSCs group and control group,baseline characteristics mscs control,C0168634|C1521970|C2248778|C0243148
86 ||| MATERIALS AND METHODS ||| 1.52 ||| The analysis of SPECT images was performed by blinded independent investigators at each participating center.,analysis spect images performed blinded independent investigators participating center,C0002778|C0040399|C1704254|C0884358|C0150108|C0085862|C0035173|C0679823|C0205099
164 ||| DISCUSSION ||| 4.16 ||| The temporal window of opportunity to maximize efficacy seems to be between the acute inflammatory response and scar formation.,temporal window opportunity maximize efficacy acute inflammatory response scar formation,C0442043|C0557702|G0000000|G0000000|C1280519|C0205178|C0333348|C0871261|C0241158|C0220781
3 |||  ||| 0.3 ||| We thus performed a randomized pilot study to investigate the safety and efficacy of MSCs in patients with AMI.,performed randomized pilot study investigate safety efficacy mscs patients ami,C0884358|C0034656|C0473169|C0557651|C1292732|C0036043|C1280519|C2248778|C0030705|G0000000
"26 |||  ||| 0.26 ||| First, bone marrow (BM)-derived mesenchymal stem cells (MSCs) are considered to be an attractive candidate because of high replicability, paracrine effect, ability to preserve potency, and no adverse reactions to allogeneic transplants (5,6).",bone marrow bm -derived mesenchymal stem cells mscs considered attractive candidate replicability paracrine ability preserve potency adverse reactions allogeneic transplants 5 6,C0262950|C0086590|C0006416|C1441547|C1513143|C0242767|C0007634|C2248778|C0750591|C2346874|G0000000|G0000000|C0597170|C0085732|G0000000|C3245505|G0000000|C0443286|C1515895|C0332835|G0000000|G0000000
"67 ||| MATERIALS AND METHODS ||| 1.33 ||| After cell injection, repeated coronary angiography was undertaken to identify antegrade flow and the absence of other possible complications.",cell injection repeated coronary angiography undertaken identify antegrade flow absence complications,C0007634|C0021485|C0205341|C0018787|C0002978|G0000000|G0000000|C0589502|C0806140|C0332197|C0009566
199 ||| DISCUSSION ||| 4.51 ||| Intracoronary administration of autologous BM-derived MSCs at 1 month is tolerable and safe with modest improvement in LVEF at 6-month follow-up.,intracoronary administration autologous bm-derived mscs 1 month tolerable safe modest improvement lvef 6-month follow-up,C0595454|C0001554|C0439859|C0006416|C2248778|G0000000|C0332177|C4053931|G0000000|C4054480|C2986411|C0428772|C0332177|C0589120
13 |||  ||| 0.13 ||| We thus performed a randomized pilot study to investigate the safety and efficacy of MSCs in patients with AMI.,performed randomized pilot study investigate safety efficacy mscs patients ami,C0884358|C0034656|C0473169|C0557651|C1292732|C0036043|C1280519|C2248778|C0030705|G0000000
"5 |||  ||| 0.5 ||| During follow-up period, 58 patients completed the trial.",follow-up period 58 patients completed trial,C0589120|C0439531|C0450371|C0030705|C0205197|C0008976
"73 ||| MATERIALS AND METHODS ||| 1.39 ||| Twenty-four hour ambulatory ECG (Holter) monitoring was done at baseline, 1 month and 6 months.",twenty-four hour ambulatory ecg holter monitoring baseline 1 month 6 months,C3715070|C0439227|C0439841|C1623258|G0000000|C0150369|C0168634|G0000000|C0332177|G0000000|C0439231
129 ||| RESULTS ||| 3.19 ||| Quantitative analyses of LV function by SPECT,quantitative analyses lv function spect,C0392762|C0002778|C0023128|C0031843|C0040399
89 ||| MATERIALS AND METHODS ||| 1.55 ||| LV regional wall motion analyses were based on grading the contractility of individual segments.,lv regional wall motion analyses based grading contractility individual segments,C0023128|C0205147|C0677535|C0026597|C0002778|C1527178|C0441800|C0026820|C0027361|C0441635
192 ||| DISCUSSION ||| 4.44 ||| The final decision was confirmed by the agreement of investigators in each participating center.,final decision confirmed agreement investigators participating center,C0205088|C0679006|C0521093|C0680240|C0035173|C0679823|C0205099
40 ||| MATERIALS AND METHODS ||| 1.6 ||| Twenty to twenty-five milliliters (mean ± SD: 23.1 ± 11.5 mL) of BM aspirates were obtained under local anesthesia from the posterior iliac crest in the MSCs group on 3.8 ± 1.5 days after admission.,twenty twenty-five milliliters sd 23 1 11 5 bm aspirates local anesthesia posterior iliac crest mscs 3 8 1 5 days admission,C0724000|C3715062|C0439242|C2699239|C0450371|G0000000|C0450371|G0000000|C0006416|C0370199|C0205276|C0002903|C0205095|C0020889|C0332243|C2248778|G0000000|G0000000|G0000000|G0000000|C0439228|C0184666
97 ||| MATERIALS AND METHODS ||| 1.63 ||| Type I and II error is set to 0.05 and 0.20 (statistical power 80%).,type ii error set 0 05 0 20 statistical power 80%,C0332307|G0000000|C0743559|C0036849|G0000000|C0450371|G0000000|C0450371|C0038215|C0032863|C0450371
44 ||| MATERIALS AND METHODS ||| 1.10 ||| They were plated at 2-3 × 10 5 cells/cm 2 into 75 cm 2 flasks.,plated 2-3 10 5 cells/cm 2 75 cm 2 flasks,C0005971|G0000000|C0450371|G0000000|C0007634|G0000000|C0450371|G0000000|G0000000|C0872171
"163 ||| DISCUSSION ||| 4.15 ||| However, the optimal time for stem-cell therapy was not precisely identified.",optimal time stem-cell therapy precisely identified,C2698651|C0040223|C0038250|C0039798|G0000000|C0205396
183 ||| DISCUSSION ||| 4.35 ||| Hovland et al.,hovland al,G0000000|C0202311
"128 ||| RESULTS ||| 3.18 ||| The improvement in LVEF was more significant in the MSCs group than in the control group according to SPECT (8.3% ± 8.3% and 1.3% ± 7.5%, P = 0.007) and echocardiography (2.0% ± 2.8% and -0.3% ± 1.5%, P = 0.003).",improvement lvef mscs control spect 8 3% 8 3% 1 3% 7 5% = 0 007 echocardiography 2 0% 2 8% -0 3% 1 5% = 0 003,C2986411|C0428772|C2248778|C0243148|C0040399|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061|C0013516|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061
138 ||| RESULTS ||| 3.28 ||| Periprocedural MI was occurred in 2 patients.,periprocedural mi occurred 2 patients,G0000000|C3810814|C1709305|G0000000|C0030705
"188 ||| DISCUSSION ||| 4.40 ||| After randomization, 11 of 69 (15.9%) patients were excluded and the main cause was poor image quality.",randomization 11 69 15 9% patients excluded main poor image quality,C0034656|C0450371|C0450371|C0450371|G0000000|C0030705|C1554077|C0205225|C0032854|C1704254|C0332306
"151 ||| DISCUSSION ||| 4.3 ||| In chronic ischemic heart failure, STAR-Heart study demonstrated that intracoronary BM cell therapy improved ventricular performance, quality-of-life and even survival (13).",chronic ischemic heart failure star-heart study demonstrated intracoronary bm cell therapy improved ventricular performance quality-of-life survival 13,C0205191|C0475224|C0018787|C0231174|C0995242|C0557651|G0000000|C0595454|C0006416|C0007634|C0039798|C0184511|C0018827|C0597198|C0332306|C0038952|C0450371
9 |||  ||| 0.9 ||| There was no treatment-related toxicity during intracoronary administration of MSCs.,treatment-related toxicity intracoronary administration mscs,C0039798|C0040539|C0595454|C0001554|C2248778
"160 ||| DISCUSSION ||| 4.12 ||| Moreover, MSC-conditioned medium directly inhibited the function of cardiac fibroblasts and resulted in a decrease of myocardial fibrosis with the consequent improvement of cardiac function by secreting antifibrotic factors such as adrenomedullin (28).",msc-conditioned medium directly inhibited function cardiac fibroblasts decrease myocardial fibrosis consequent improvement cardiac function secreting antifibrotic factors adrenomedullin 28,C0009647|C0009458|C1947931|C0311403|C0031843|C0018787|C0016030|C0392756|C0027061|C0016059|C3845876|C2986411|C0018787|C0031843|C1327616|G0000000|C1521761|C0215825|C0450371
170 ||| DISCUSSION ||| 4.22 ||| Nearly 90% of our patients were prescribed statin at discharge.,90% patients prescribed statin discharge,C0450371|C0030705|C0278329|C0360714|C0012621
167 ||| DISCUSSION ||| 4.19 ||| The use of statin may ameliorate the microenvironment of injured myocardium and protect implanted MSCs.,statin ameliorate microenvironment injured myocardium protect implanted mscs,C0360714|G0000000|G0000000|C0332664|C0027061|G0000000|C0021102|C2248778
18 |||  ||| 0.18 ||| The absolute improvement in the LVEF by SPECT at 6 month was greater in the BM-derived MSCs group than in the control group (5.9% ± 8.5% vs 1.6% ± 7.0%; P = 0.037).,absolute improvement lvef spect 6 month bm-derived mscs control 5 9% 8 5% 1 6% 7 0% = 0 037,C0205344|C2986411|C0428772|C0040399|G0000000|C0332177|C0006416|C2248778|C0243148|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061
"56 ||| MATERIALS AND METHODS ||| 1.22 ||| The criteria for the release of MSCs for clinical use included viability > 80%, absence of microbial contamination (bacteria, fungus, virus, and mycoplasma) if undertaken 3-4 days before administration, and expression of CD73 and CD105 by > 90% of cells and absence of CD14, CD34, and CD45 by < 3% of cells as assessed by flow cytometry (data not shown).",criteria release mscs clinical included viability 80% absence microbial contamination bacteria fungus virus mycoplasma undertaken 3-4 days administration expression cd73 cd105 90% cells absence cd14 cd34 cd45 < 3% cells assessed flow cytometry data,C0243161|C0030685|C2248778|C0205210|C0332257|C0443348|C0450371|C0332197|C0599840|C0259846|C0004611|C0016832|C0042776|C0026934|G0000000|G0000000|C0439228|C0001554|C0185117|G0000000|G0000000|C0450371|C0007634|C0332197|G0000000|G0000000|G0000000|G0000000|G0000000|C0007634|C1516048|C0806140|C0814048|C1511726
53 ||| MATERIALS AND METHODS ||| 1.19 ||| We performed rescue PCI when ST-segment resolution was < 50% at follow-up electrocardiography 90 min after thrombolytic therapy.,performed rescue pci st-segment resolution < 50% follow-up electrocardiography 90 min thrombolytic therapy,C0884358|G0000000|C4049621|C0429029|C1514893|G0000000|C0450371|C0589120|C0013798|C0450371|C0702093|C0016018|C0039798
124 ||| RESULTS ||| 3.14 ||| Volumetric analyses of LV end-diastole and end-systole at baseline and 6 months and the changes at 6 months showed no significant differences between groups.,volumetric analyses lv end-diastole end-systole baseline 6 months 6 months differences,C0445383|C0002778|C0023128|C1562146|C0489485|C0168634|G0000000|C0439231|G0000000|C0439231|C1705241
85 ||| MATERIALS AND METHODS ||| 1.51 ||| The computer calculated resting global LVEF from the gated SPECT images using an automated algorithm (20).,computer calculated resting global lvef gated spect images automated algorithm 20,C0009622|C0444686|C0035253|C0205246|C0428772|G0000000|C0040399|C1704254|C0205554|C0002045|C0450371
"194 ||| DISCUSSION ||| 4.46 ||| Finally, we did not evaluate the inter-and intra-observer variability in radiographic measurements.",finally evaluate inter-and intra-observer variability radiographic measurements,G0000000|C0220825|C0205103|C0347985|C2827666|C0444708|C0242485
"15 |||  ||| 0.15 ||| During follow-up period, 58 patients completed the trial.",follow-up period 58 patients completed trial,C0589120|C0439531|C0450371|C0030705|C0205197|C0008976
205 ||| DISCLOSURE ||| 5.6 ||| Ejection fraction and left ventricular volume as determined by SPECT and echocardiography,ejection fraction left ventricular volume determined spect echocardiography,C0302131|C1264633|C0205091|C0018827|C0449468|G0000000|C0040399|C0013516
111 ||| RESULTS ||| 3.1 ||| Study participants and baseline characteristics,study participants baseline characteristics,C0557651|C0679646|C0168634|C1521970
158 ||| DISCUSSION ||| 4.10 ||| Stromal cellderived factor (SDF)-1α is a major chemotactic paracrine factor for homing stem cells.,stromal cellderived factor sdf -1 major chemotactic paracrine factor homing stem cells,C0927195|G0000000|C1521761|G0000000|G0000000|C0205082|C0008018|C0597170|C1521761|G0000000|C0242767|C0007634
"174 ||| DISCUSSION ||| 4.26 ||| However, there was no mortality benefit by opening the occluded artery after 6 hr (31).",mortality benefit occluded artery 6 hr 31,C0026565|C0814225|C0028778|C0003842|G0000000|G0000000|C0450371
39 ||| MATERIALS AND METHODS ||| 1.5 ||| Preparation of autologous MSCs,preparation autologous mscs,C1521827|C0439859|C2248778
112 ||| RESULTS ||| 3.2 ||| Eighty patients were screened and 69 patients (86.3%) were included and randomly assigned to the MSCs group (n = 33) or control group (n = 36).,patients screened 69 patients 86 3% included randomly assigned mscs = 33 control = 36,C0030705|C0220908|C0450371|C0030705|C0450371|G0000000|C0332257|G0000000|C1516050|C2248778|G0000000|C0450371|C0243148|G0000000|C0450371
"29 |||  ||| 0.29 ||| Although STAR-Heart study showed beneficial effects of BMCs in patients with chronic heart failure (13), there is little evidence of best time to treat AMI with stem cells (14).",star-heart study beneficial effects bmcs patients chronic heart failure 13 evidence time treat ami stem cells 14,C0995242|C0557651|G0000000|C1280500|C0065839|C0030705|C0205191|C0018787|C0231174|C0450371|C3887511|C0040223|C0087111|G0000000|C0242767|C0007634|C0450371
171 ||| DISCUSSION ||| 4.23 ||| This synergic effect of statin might contribute to the functional recovery of damaged myocardium in our study.,synergic statin contribute functional recovery damaged myocardium study,G0000000|C0360714|C1880177|C0205245|C0237820|C0010957|C0027061|C0557651
"21 |||  ||| 0.21 ||| In conclusion, the intracoronary infusion of human BM-derived MSCs at 1 month is tolerable and safe with modest improvement in LVEF at 6-month follow-up by SPECT.",conclusion intracoronary infusion human bm-derived mscs 1 month tolerable safe modest improvement lvef 6-month follow-up spect,C1707478|C0595454|C0574032|C0086418|C0006416|C2248778|G0000000|C0332177|C4053931|G0000000|C4054480|C2986411|C0428772|C0332177|C0589120|C0040399
59 ||| MATERIALS AND METHODS ||| 1.25 ||| Immunostaining with α-sarcomeric actin and troponin T was used to demonstrate the cardiomyogenic differentiation.,immunostaining -sarcomeric actin troponin demonstrate cardiomyogenic differentiation,G0000000|C0036225|C0001271|C0041199|G0000000|G0000000|C0007589
8 |||  ||| 0.8 ||| The absolute improvement in the LVEF by SPECT at 6 month was greater in the BM-derived MSCs group than in the control group (5.9% ± 8.5% vs 1.6% ± 7.0%; P = 0.037).,absolute improvement lvef spect 6 month bm-derived mscs control 5 9% 8 5% 1 6% 7 0% = 0 037,C0205344|C2986411|C0428772|C0040399|G0000000|C0332177|C0006416|C2248778|C0243148|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061
81 ||| MATERIALS AND METHODS ||| 1.47 ||| Sixty-four images were obtained over a 180° orbit using 90° between the heads.,sixty-four images 180 orbit 90 heads,C3816724|C1704254|C1442061|C0029180|C0450371|C0018670
133 ||| RESULTS ||| 3.23 ||| Safety and clinical outcomes,safety clinical outcomes,C0036043|C0205210|C1274040
"52 ||| MATERIALS AND METHODS ||| 1.18 ||| If primary PCI was not available, a thrombolytic agent was used to reperfuse the occluded artery.",primary pci thrombolytic agent reperfuse occluded artery,C0205225|C4049621|C0016018|C0450442|G0000000|C0028778|C0003842
142 ||| RESULTS ||| 3.32 ||| 1.7 ± 0.8 1.7 ± 0.9 0.815 Symptom to follow-up Echo (day) 182.6 ± 6.0 179.5 ± 7.4 0.084,1 7 0 8 1 7 0 9 0 815 symptom follow-up echo day 182 6 6 0 179 5 7 4 0 084,G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061|C1457887|C0589120|C0058928|C0332173|C1442061|G0000000|G0000000|G0000000|C1442061|G0000000|G0000000|G0000000|G0000000|C1442061
186 ||| DISCUSSION ||| 4.38 ||| Ten of 40 (25%) in treatment group and 12/40 (30%) in control group were excluded.,ten 40 25% treatment 12/40 30% control excluded,C0014518|C0450371|C0450371|C0039798|C0450371|C0450371|C0243148|C1554077
148 ||| RESULTS ||| 3.38 ||| Paroxysmal non-sustained atrial fibrillation was found in 2 patients of the MSCs group (1 patient after PCI and 1 patient at 1 month follow-up) and in 1 patient of the control group after PCI.,paroxysmal non-sustained atrial fibrillation 2 patients mscs 1 patient pci 1 patient 1 month follow-up 1 patient control pci,C0205311|C1518422|C0018792|C0232197|G0000000|C0030705|C2248778|G0000000|C0030705|C4049621|G0000000|C0030705|G0000000|C0332177|C0589120|G0000000|C0030705|C0243148|C4049621
136 ||| RESULTS ||| 3.26 ||| Patients had no or mild angina during balloon inflation for infusion of MSCs.,patients mild angina balloon inflation infusion mscs,C0030705|C2945599|C0002962|C0336867|C0021398|C0574032|C2248778
"146 ||| RESULTS ||| 3.36 ||| There were no deaths, MI, TVR, stent thrombosis, life-threatening arrhythmia or stroke in both groups during 6-month follow-up.",deaths mi tvr stent thrombosis life-threatening arrhythmia stroke 6-month follow-up,C0011065|C3810814|G0000000|C0038257|C0040053|C1517874|C0003811|C0038454|C0332177|C0589120
20 |||  ||| 0.20 ||| No significant adverse cardiovascular events occurred during follow-up.,adverse cardiovascular events occurred follow-up,G0000000|C0007226|C0441471|C1709305|C0589120
"91 ||| MATERIALS AND METHODS ||| 1.57 ||| The basal and mid-levels were subdivided into six segments, and the apical level subdivided into four segments.",basal mid-levels subdivided segments apical level subdivided segments,C0205112|C0444598|G0000000|C0441635|C0205111|C0441889|G0000000|C0441635
7 |||  ||| 0.7 ||| We also evaluated treatment-related adverse events.,evaluated treatment-related adverse events,C0220825|C0039798|G0000000|C0441471
"93 ||| MATERIALS AND METHODS ||| 1.59 ||| In this scoring system, higher scores indicated more severe abnormality in the motion of the wall: 1) normokinesis, 2) hypokinesis, 3) akinesis, 4) dyskinesis, and 5) aneurysm.",scoring system scores severe abnormality motion wall 1 normokinesis 2 hypokinesis 3 akinesis 4 dyskinesis 5 aneurysm,C0449820|C0449913|C0449820|C0205082|C1704258|C0026597|C0677535|G0000000|G0000000|G0000000|C0086439|G0000000|C0233568|G0000000|C0013384|G0000000|C0002940
"181 ||| DISCUSSION ||| 4.33 ||| Although CMR was considered to be the ""gold standard"" for evaluation of LV function, it was impossible to use CMR at all institutions for the first time.",cmr considered gold standard evaluation lv function impossible cmr institutions time,C0006802|C0750591|C0018026|C1442989|C0220825|C0023128|C0031843|G0000000|C0006802|C1272753|C0040223
"76 ||| MATERIALS AND METHODS ||| 1.42 ||| MACE was defined as the composites of any cause of death, myocardial infarction, revascularization of the target vessel, re-hospitalization for heart failure, and life-threatening arrhythmia.",mace defined composites death myocardial infarction revascularization target vessel re-hospitalization heart failure life-threatening arrhythmia,C0349381|C1704788|C0205199|C0011065|C0027061|C0021308|C0581603|C1521840|C0005847|C0556581|C0018787|C0231174|C1517874|C0003811
"84 ||| MATERIALS AND METHODS ||| 1.50 ||| Vendor-specific, computer-enhanced edge detection methods were used to assess the LV epicardial and endocardial margins during the entire cardiac cycle.",vendor-specific computer-enhanced edge detection methods assess lv epicardial endocardial margins entire cardiac cycle,C0042462|C0009622|C0205154|C1511790|C0025663|C1516048|C0023128|C0442016|C0014124|C0205284|C0439751|C0018787|C1511572
"190 ||| DISCUSSION ||| 4.42 ||| However, there may be little possibility for selection bias, because radiologists were blinded to treatment information.",possibility selection bias radiologists blinded treatment,C0332149|C0036576|C0242568|C0260194|C0150108|C0039798
"46 ||| MATERIALS AND METHODS ||| 1.12 ||| After 5-7 days, non-adherent cells were removed by replacing the medium; adherent cells were cultured for another 2-3 days.",5-7 days non-adherent cells removed replacing medium adherent cells cultured 2-3 days,G0000000|C0439228|C1518422|C0007634|C0849355|C1299987|C0009458|C0334154|C0007634|C0010453|G0000000|C0439228
48 ||| MATERIALS AND METHODS ||| 1.14 ||| Cells were serially subcultured up to passage 4 or passage 5 for infusion (mean ± SD: 4.4 ± 0.5 passages).,cells serially subcultured passage 4 passage 5 infusion sd 4 4 0 5 passages,C0007634|G0000000|C0200940|C0439799|G0000000|C0439799|G0000000|C0574032|C2699239|G0000000|G0000000|G0000000|G0000000|C0439799
109 ||| Ethics statement ||| 2.4 ||| The changes of LVEDV and LVESV also did not significantly different at 6-month follow-up in either group.,lvedv lvesv 6-month follow-up,G0000000|G0000000|C0332177|C0589120
"144 ||| RESULTS ||| 3.34 ||| MSC, mesenchymal stem cell; ACEi, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; SPECT, single-photon emission computed tomography; Echo, echocardiography.",msc mesenchymal stem cell acei angiotensin-converting enzyme inhibitor arb angiotensin receptor blocker bp blood pressure spect single-photon emission computed tomography echo echocardiography,G0000000|C1513143|C0242767|C0007634|G0000000|C0003018|C0014442|C1999216|C3888198|C0003018|C0597357|G0000000|C0037623|C0005767|C0033095|C0040399|C0037179|C0233929|C1441526|C0040395|C0058928|C0013516
168 ||| DISCUSSION ||| 4.20 ||| Animals treated with atorvastatin showed the improvement of myocardial perfusion and contractility compared with untreated animals by Yang et al.,animals treated atorvastatin improvement myocardial perfusion contractility compared untreated animals yang al,C0003062|C1522326|C0286651|C2986411|C0027061|C0031001|C0026820|C1707455|C0332155|C0003062|C2945617|C0202311
"43 ||| MATERIALS AND METHODS ||| 1.9 ||| Cells were resuspended in Dulbecco's modified Eagle's medium-low glucose (DMEM; Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Gibco), 100 U/mL penicillin/100 μg/mL and streptomycin (Gibco).",cells resuspended dulbeccos modified eagles medium-low glucose dmem gibco grand island ny usa 10% fetal bovine serum gibco 100 u/ml penicillin/100 g/ml streptomycin gibco,C0007634|G0000000|G0000000|C0392747|C0325564|C0009458|C0017725|G0000000|G0000000|G0000000|C0022130|C0027976|C0041703|C0450371|C0015965|C0007452|C0229671|G0000000|C1442061|C0439340|C0030827|C1300565|C0038425|G0000000
6 |||  ||| 0.6 ||| The primary endpoint was changes in left ventricular ejection fraction (LVEF) by single-photon emission computed tomography (SPECT) at 6 month.,primary endpoint left ventricular ejection fraction lvef single-photon emission computed tomography spect 6 month,C0205225|C2349179|C0205091|C0018827|C0302131|C1264633|C0428772|C0037179|C0233929|C1441526|C0040395|C0040399|G0000000|C0332177
134 ||| RESULTS ||| 3.24 ||| All procedures related to the BM aspiration and stem cell transplantation were well tolerated.,procedures bm aspiration stem cell transplantation tolerated,C0025664|C0006416|C0220787|C0242767|C0007634|C0040732|G0000000
"36 ||| MATERIALS AND METHODS ||| 1.2 ||| From March 2007 to September 2010, total 80 patients were enrolled from three tertiary hospitals in Korea.",march 2007 september 2010 total 80 patients enrolled tertiary hospitals korea,C3829202|G0000000|C3828193|G0000000|C0439175|C0450371|C0030705|G0000000|C0205372|C0019994|C0022771
35 ||| MATERIALS AND METHODS ||| 1.1 ||| Study design and population,study design population,C0557651|C1707689|C0032659
105 ||| MATERIALS AND METHODS ||| 1.71 ||| Data were analyzed using SPSS for Windows ver.,data analyzed spss windows ver,C1511726|C0936012|C3813609|C0557702|C0302357
187 ||| DISCUSSION ||| 4.39 ||| It was larger than we had anticipated.,larger anticipated,C0549177|C3840775
69 ||| MATERIALS AND METHODS ||| 1.35 ||| The mean duration of cultured MSCs from BM aspiration to intracoronary injection was 25.0 ± 2.4 days.,duration cultured mscs bm aspiration intracoronary injection 25 0 2 4 days,C0449238|C0010453|C2248778|C0006416|C0220787|C0595454|C0021485|C0450371|G0000000|G0000000|G0000000|C0439228
126 ||| RESULTS ||| 3.16 ||| We analyzed the subgroup population treated < 6 hr from symptom onset to first balloon inflation.,analyzed subgroup population treated < 6 hr symptom onset balloon inflation,C0936012|C1079230|C0032659|C1522326|G0000000|G0000000|G0000000|C1457887|C0206132|C0336867|C0021398
